NurExone Biologic Inc., a biopharmaceutical innovator in exosome-based regenerative therapies, is pleased to announce that its U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), is planning to establish its first U.S. commercial exosome production facility in Indianapolis, Indiana.

The Indianapolis facility would serve as Exo-Top’s U.S. manufacturing base, transferring NurExone’s proprietary exosome production process into the American market. The GMP compliant site would produce exosomes both for NurExone’s therapeutic pipeline and for a growing business-to-business opportunity in regenerative aesthetics.

“Indiana’s commitment to building its life sciences cluster, outstanding logistics and strong incentives offer make Indianapolis the ideal home for Exo-Top, and we are honored to consider expanding into Indiana with the support of the Indiana Office of Commerce,” said Jacob Licht, CEO of Exo-Top. “By joining this ecosystem, we would contribute to Indiana’s biomanufacturing growth while securing a U.S. foundation for our therapeutic and commercial programs.”

“Indiana would be a natural fit for Exo-Top’s U.S. establishment, and we look forward to the potential high-quality jobs and local economic benefits this investment would create,” said Secretary of Commerce David Adams. “The state offers the right environment for Exo-Top to scale production and strengthen NurExone’s U.S. supply chain.”

Indiana is home to one of the largest life sciences sectors in the U.S., generating more than $99 billion in annual economic outputⁱ and attracting over $1.5 billion in venture investments since 2019ⁱⁱ. Industry employment has grown nearly seven times faster than the broader private sector, supported by global anchors such as Eli Lilly and advanced logistics infrastructureⁱⁱⁱ. These strengths make Indiana a strategic and attractive location for companies like Exo-Top preparing to scale.

Exo-Top’s potential new Indianapolis operations would anchor NurExone’s North American presence, complementing the Company’s progress toward first-in-human clinical trials of ExoPTEN and its plans to uplist to a major U.S. stock exchange.